NASDAQ:INNT Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free INNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.56▼$1.4252-Week Range N/AVolume50 shsAverage Volume525,982 shsMarket Capitalization$8,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Innovate Biopharmaceuticals alerts: Email Address Ad Stansberry ResearchDo This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Read More Ad Stansberry ResearchDo This Today BEFORE Biden Wins in NovemberDiscover "U.S.'s New Money" Before Biden Wins A new form of money has emerged in America, and it's making some folks wildly rich… (Musk and Bezos both use it).Find out how you can too in this free video. INNT Stock News HeadlinesMay 10, 2024 | benzinga.comLirum Therapeutics, Inc IPOs Tomorrow, Here's What You Need To KnowMay 7, 2024 | markets.businessinsider.comNuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business HighlightsMay 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 6, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global ConferenceMay 3, 2024 | finanznachrichten.deArdelyx, Inc.: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 3, 2024 | uk.finance.yahoo.comDecoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT InsightMay 3, 2024 | finanznachrichten.deWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)May 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 1, 2024 | markets.businessinsider.comStrategic Advisory for Leading Therapeutics Innovation Inc. (SALTI) Launches as New Management Consulting FirmApril 30, 2024 | tmcnet.comCaris Life Sciences and COTA, Inc. Announce Collaboration to Expand Collective Multi-Modal Data OfferingApril 30, 2024 | msn.comOcugen to Present Pioneering Gene Therapy Data at Retinal Innovation SummitApril 30, 2024 | finance.yahoo.comReflect Scientific Inc Secures $550,000 Sale with Major BioPharma CompanyApril 27, 2024 | bizjournals.comAll about preservation — Innovation Campus Phase 1April 26, 2024 | finance.yahoo.comRakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate UpdateApril 23, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals to Present at the LSX World Congress 2024April 22, 2024 | finance.yahoo.comSystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive OfficerApril 19, 2024 | msn.comInnovate Change - best online casinos review by the experts 2024April 18, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic RetinopathyApril 15, 2024 | finance.yahoo.comThird Harmonic Bio Inc CEO Natalie Holles Sells 13,558 SharesApril 15, 2024 | finance.yahoo.comAmerican Thoracic Society Selects Vasomune Therapeutics, Inc., to Present the AV-001 Development Update at the 2024 Respiratory Innovation SummitApril 12, 2024 | tmcnet.comUniversity of Phoenix Office of Educational Equity Leadership Presents at 2024 OLC Innovate ConferenceApril 10, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsApril 10, 2024 | finanznachrichten.deIN8bio, Inc: IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024April 9, 2024 | finance.yahoo.comNIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing ProjectsApril 9, 2024 | stockhouse.comSynaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsApril 9, 2024 | tmcnet.comSyncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024See More Headlines Receive INNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2019Today5/10/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INNT CUSIPN/A CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,050,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-234.42% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / BookN/AMiscellaneous Outstanding Shares41,325,000Free FloatN/AMarket Cap$8,000.00 OptionableNot Optionable Beta-0.39 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Sandeep Laumas M.D. (Age 50)CEO & Exec. Chairman Mr. Jay P. Madan M.S. (Age 53)Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director Dr. Christopher P. Prior (Age 66)Consultant Jerry Gardner M.D.Head of Clinical StrategyDr. Patrick H. Griffin (Age 64)Chief Medical Officer Key CompetitorsOncoSec MedicalNASDAQ:ONCSQNVN LiquidationNASDAQ:NOVNQMinerva SurgicalNASDAQ:UTRSGenocea BiosciencesNASDAQ:GNCAHTG Molecular DiagnosticsNASDAQ:HTGMQView All Competitors INNT Stock Analysis - Frequently Asked Questions How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11). What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), SCYNEXIS (SCYX), Micron Technology (MU), Nabriva Therapeutics (NBRV), Neurotrope (NTRP) and This page (NASDAQ:INNT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
